Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
883.2 USD | -0.84% | -1.52% | +0.56% |
Apr. 26 | Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says | MT |
Apr. 26 | Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 | MT |
Chart calendar Regeneron Pharmaceuticals, Inc.
Upcoming events on Regeneron Pharmaceuticals, Inc.
Past events on Regeneron Pharmaceuticals, Inc.
2024-03-13 10:40 am | Leerink Partners Global Biopharma Conference |
2024-03-12 11:15 am | Barclays Global Healthcare Conference |
2024-03-06 11:10 am | TD Cowen Health Care Conference |
2024-02-14 01:20 pm | Oppenheimer Healthcare Life Sciences Conference |
2024-02-02 08:30 am | Q4 2023 Earnings Call |
2024-02-02 06:30 am | Q4 2023 Earnings Release |
2024-01-08 05:15 pm | JPMorgan Healthcare Conference |
2023-12-14 08:30 am | Business Update Call |
2023-12-11 09:00 pm | American Society of Hematology Meeting - Abstract No 3841 |
2023-12-11 09:00 pm | American Society of Hematology Meeting - Abstract No 4746 |
2023-12-11 09:00 pm | American Society of Hematology Meeting - Abstract No 4461 |
2023-12-11 | American Society of Hematology Meeting - Abstract No 912 |
2023-12-11 09:00 pm | American Society of Hematology Meeting - Abstract No 4504 |
2023-12-10 09:00 pm | American Society of Hematology Meeting - Abstract No 2550 |
2023-12-10 09:00 pm | American Society of Hematology Meeting - Abstract No 2716 |
2023-12-10 09:00 pm | American Society of Hematology Meeting - Abstract No 3752 |
2023-12-10 09:00 pm | American Society of Hematology Meeting - Abstract No 3773 |
2023-12-10 09:00 pm | American Society of Hematology Meeting - Abstract No 3393 |
2023-12-10 09:00 pm | American Society of Hematology Meeting - Abstract No 3359 |
2023-12-10 09:00 pm | American Society of Hematology Meeting - Abstract No 3100 |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 7 863 7 816 0.61% | 8 497 8 494 0.04% | 16 072 15 679 2.51% | 12 173 11 850 2.73% | 13 117 12 921 1.52% | 13 907 |
EBITDA Million USD | Released Forecast Spread | 3 420 3 610 -5.28% | 4 245 4 158 2.09% | 9 835 9 709 1.29% | 6 060 6 161 -1.63% | 5 547 5 452 1.74% | 5 538 |
EBIT Million USD | Released Forecast Spread | 2 210 2 285 -3.29% | 3 577 3 485 2.64% | 8 947 9 034 -0.96% | 5 719 5 561 2.84% | 5 126 5 082 0.87% | 5 230 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 2 429 2 308 5.26% | 3 810 3 582 6.39% | 9 326 9 442 -1.23% | 4 859 4 812 0.97% | 4 199 4 276 -1.8% | 4 720 |
Net income Million USD | Released Forecast Spread | 2 116 1 998 5.87% | 3 513 3 160 11.18% | 8 075 8 014 0.77% | 4 338 4 166 4.14% | 3 954 3 808 3.83% | 4 320 |
EPS USD | Released Forecast Spread | 18,5 17,6 4.67% | 30,5 28,0 8.96% | 72,0 71,1 1.17% | 38,2 36,3 5.31% | 34,8 33,9 2.62% | 36,9 |
Announcement Date | 06/02/20 | 05/02/21 | 04/02/22 | 03/02/23 | 02/02/24 | - |
Quarterly results
Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 4 952 4 526 9.4% | 2 965 2 690 10.22% | 2 857 2 797 2.14% | 2 936 2 870 2.29% | 3 414 3 113 9.7% | 3 162 2 998 5.48% | 3 158 3 025 4.41% | 3 363 3 222 4.36% | 3 434 3 287 4.49% | 3 222 | 3 408 | 3 576 | 3 732 | 3 582 |
EBITDA Million USD | Released Forecast Spread | 2 903 2 564 13.21% | 1 558 1 376 13.24% | 1 344 1 220 10.17% | 1 488 1 344 10.67% | 1 637 1 336 22.54% | 1 315 1 219 7.84% | 1 351 1 175 14.98% | 1 488 1 288 15.47% | 1 395 1 500 -7.01% | 1 195 | 1 320 | 1 440 | 1 606 | 1 290 |
EBIT Million USD | Released Forecast Spread | 2 640 2 601 1.5% | 1 483 1 273 16.56% | 1 285 1 124 14.37% | 1 413 1 266 11.62% | 1 537 1 344 14.33% | 1 215 1 203 1.01% | 1 248 1 216 2.63% | 1 382 1 272 8.7% | 1 282 1 248 2.74% | 1 170 | 1 262 | 1 376 | 1 444 | 1 400 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 2 503 2 649 -5.51% | 1 061 1 185 -10.43% | 963 1 116 -13.71% | 1 510 984 53.36% | 1 325 1 154 14.81% | 858 1 009 -14.97% | 1 083 1 041 4% | 1 111 1 154 -3.72% | 1 148 1 308 -12.24% | 1 212 | 1 304 | 1 432 | 1 287 | |
Net income Million USD | Released Forecast Spread | 2 229 2 108 5.74% | 974 1 038 -6.2% | 852 794 7.38% | 1 316 845 55.67% | 1 197 1 060 12.94% | 818 876 -6.69% | 968 885 9.42% | 1 008 1 071 -5.9% | 1 160 1 025 13.08% | 888 | 1 032 | 1 179 | 1 264 | 1 283 |
EPS USD | Released Forecast Spread | 19,7 19,4 1.32% | 8,61 8,77 -1.86% | 7,47 7,38 1.29% | 11,7 7,93 47.05% | 10,5 9,23 13.73% | 7,17 7,96 -9.92% | 8,50 7,93 7.12% | 8,89 9,04 -1.62% | 10,2 9,21 10.69% | 7,91 | 9,19 | 10,0 | 10,2 | 11,5 |
Announcement Date | 04/02/22 | 04/05/22 | 03/08/22 | 03/11/22 | 03/02/23 | 04/05/23 | 03/08/23 | 02/11/23 | 02/02/24 | - | - | - | - | - |
Past sector events for Regeneron Pharmaceuticals, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- REGN Stock
- Calendar Regeneron Pharmaceuticals, Inc.